Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. (Q27852191)

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1 reference

1 reference

1 reference

Esther Martínez-Martínez

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Irene Guijarro-Muñoz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Clara Salas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antonio Sánchez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jose M García

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

12 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

572

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

The cancer biomarker problem

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

EPHB4 and survival of colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Determinants of RNA quality from FFPE samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Coexpression of ephrin-Bs and their receptors in colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Paradoxes of the EphB4 receptor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

EphB receptor activity suppresses colorectal cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Eph receptors and ephrins in cancer: bidirectional signalling and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0572-1

Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.

21 January 2018

1 reference

12 December 2020

Gene expression in colorectal cancer

1 reference

12 December 2020

Costly cancer drugs trigger proposals to modify clinical trial design

1 reference

12 December 2020

Identification of gene signatures for invasive colorectal tumor cells

1 reference

12 December 2020

Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts

1 reference

12 December 2020

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

1 reference

12 December 2020

10.1007/S12032-013-0572-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

28 February 2020

1018021223

0 references

2 references

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23579861%20AND%20SRC:MED&resulttype=core&format=json